Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-005748

PRESIDENT AND CEO sold 12,000 shares at an average $16.89 ($202,653)

  • PRESIDENT AND CEO acquired 12,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-02-26 Exercise or conversion : show line 1 in the form 10b5-1 +12,000 $1.12 $13,440 12,000 D
2024-02-26 Sale : show line 2 in the form 10b5-1 −7,624 $16.69 $127,219 4,376 D
2024-02-26 Sale : show line 3 in the form 10b5-1 −4,376 $17.24 $75,435 0 D
Open-market sales · 12,000 sh · avg $16.89 · $202,653

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-02-26 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −12,000 272,550 D
Loading xslF345X05/form4-02282024_100201.xml…